Tigecycline causes loss of cell viability mediated by mitochondrial OXPHOS and RAC1 in hepatocellular carcinoma cells

Tigecycline causes loss of cell viability mediated by mitochondrial OXPHOS and RAC1 in hepatocellular carcinoma cells

Abstract Background Despite recent advances in locoregional, systemic, and novel checkpoint inhibitor treatment, hepatocellular carcinoma (HCC) is still associated with poor prognosis. The feasibility of potentially curative liver resection (LR) and transplantation (LT) is limited by the underlying...

Full description

Bibliographic Details
Main Authors: Dominik T. Koch, Haochen Yu, Iris Beirith, Malte Schirren, Moritz Drefs, Yunfei Liu, Mathilda Knoblauch, Dionysios Koliogiannis, Weiwei Sheng, Enrico N. De Toni, Alexandr V. Bazhin, Bernhard W. Renz, Markus O. Guba, Jens Werner, Matthias Ilmer
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Journal of Translational Medicine
Subjects:
Tigecycline
HCC
Drug repurposing
Mitochondrial oxidative phosphorylation
RAC1
ROS
Online Access:https://doi.org/10.1186/s12967-023-04615-4

Internet

https://doi.org/10.1186/s12967-023-04615-4

Similar Items